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G-protein coupled receptorBreast cancermetastasis to the bone, potentially facilitated by chemotactic and angiogenic cytokines, contributes
to a dramatic osteolytic effect associated with this invasive behavior. Based on the intrinsic ability of calcium
sensing receptor (CaSR) to control hormonal secretion and considering its expression in the breast, we hypoth-
esized that CaSR plays a chemotactic and proangiogenic role in highly invasive MDA-MB-231 breast cancer cells
by promoting secretion of multiple cytokines. In this study, we show that MDA-MB-231 cells stimulated with R-
568 calcimimetic and extracellular calcium secreted multiple cytokines and growth factors that induced endo-
thelial cell migration and in vitro angiogenesis. These effects were dependent on the activity of CaSR as demon-
strated by the inhibitory effect of either anti-CaSR blocking monoclonal antibodies or calcilytic NPS-2143.
Moreover, CaSR knockdown prevented the proangiogenic effect of CaSR agonists. Importantly, CaSR promoted
secretion of pleiotropicmolecules like GM-CSF, EGF, MDC/CCL22, FGF-4 and IGFBP2, all known to be chemotactic
mediators with putative angiogenic factor properties. In contrast, constitutive secretion of IL-6 and β-NGF was
attenuated by CaSR. In the case of normal mammary cells, secretion of IL-6 was stimulated by CaSR, whereas a
constitutive secretion of RANTES, Angiogenin and OncostatinMwas attenuated by this receptor. Taken together,
our results indicate that an altered secretion of chemotactic and proangiogenic cytokines in breast cancer cells is
modulated by CaSR, which can be considered a potential target in the therapy of metastatic breast cancer.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Calcium sensing receptor (CaSR), one of the most clinically rele-
vant members of the family C of G-protein coupled receptors, was
cloned 20 years ago and is widely recognized as a pivotal regulator
of extracellular calcium homeostasis. In parathyroid and thyroid
glands, this receptor serves as a sensor that, in response to ﬂuctua-
tions of extracellular calcium, orchestrates the secretion of peptide
hormones. While it inhibits secretion of PTH, it promotes the release
of calcitonin, which targets kidneys and bone to play a fundamental
role adjusting extracellular levels of calcium according to homeo-
static demands [1–8].
Pathological consequences of aberrant CaSR signaling are evident in
diverse innate and chronic disorders showing an altered sensitivity to, CINVESTAV-IPN, Av. Instituto
07360 México, D.F., México.
).ﬂuctuating levels of extracellular calcium, with the consequent failure
to properly adjust the hormonal response required to control calcium
homeostasis. For instance, patients with chronic kidney disease fre-
quently have decreased bone density due to excessive urinary loss of
calcium and increased removal of this ion from the bone. Individuals
with genetically altered variants of CaSR, having either activating or
inactivating mutations, show impaired sensitivity to extracellular calci-
um manifested by imprecise control of PTH secretion. Thus, genetic
alterations in the coding sequence of CaSR, as well as changes of its
expression in diverse tissues, clearly contribute to pathological pro-
cesses, mainly related to calcium homeostasis, but also linked to addi-
tional effects of CaSR in speciﬁc cellular settings. Emerging evidences
link mutations of CaSR as well as alterations of its expression as po-
tential contributors to the progression of benign and malignant tu-
mors [2,9–12].
Although themost conspicuous physiological andpathological effects
of CaSR are linked to its functions at the parathyroid and thyroid glands,
it is now clear that CaSR is endogenously expressed in many other
tissues, where it exerts a diversity of effects beyond its known role as a
controller of extracellular calcium. CaSR promotes cell proliferation, via
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through the effects on the actin cytoskeleton. It also contributes to cell-
speciﬁc events, such as axonal and dendritic growth in neurons, and en-
graftment of stem cells at the bone [13–16]. In normal mammary
glands, CaSR inhibits PTHrP secretion and, during lactation, it regulates
the content of calcium in the milk [17–20]. In contrast, in breast cancer
cells, CaSR promotes secretion of PTHrP, resulting in the activation of os-
teoclastswhich cause a dramatic osteolytic effect, further sustained by a
“vicious cycle” linked to bone metastasis. This effect is facilitated by a
local increase of cytokines including RANKL and TGF-β, among others
[21–24].
In physiological settings, CaSR activities aremediated by its coupling
to Gq/11, Gi and G12/13 heterotrimeric G-proteins which, through intra-
cellular calcium mobilization, adenylyl cyclase inhibition or activation
of RhoA GTPase, modulate the phosphorylation of protein substrates
of PKC, PKA, Rock, MAPK and AKT [2,8,25]. Diversiﬁcation of CaSR sig-
naling capabilities is further increased by CaSR-interacting proteins,
such as β-arrestins, ﬁlamin, dorﬁn, RAMPS and AMSH, and by its com-
munication with EGF receptor, β-catenin and Wnt5a/Ror2 pathways
[26–34]. In pathological circumstances, the spectrum of CaSR signaling
capabilities can be broadened. In breast cancer cells, for instance, CaSR
is highly expressed [35] and, at least in MCF7 cells, abnormally couples
to Gs [36,37].
Knowing that ﬂuctuations of extracellular calcium affect secretory
pathways in diverse cellular settings, we hypothesized that CaSR, en-
dogenously expressed in metastatic MDA-MB-231 breast cancer cells
[38], regulates the secretion of chemotactic and pro-angiogenic factors
that activate endothelial cell migration and promote morphological
changes compatible with an angiogenic phenotype [39,40]. In the
current study, we demonstrate that, indeed, CaSR not only induces se-
cretion of chemotactic and proangiogenic cytokines by MDA-MB-231
breast cancer cells, including GM-SF, EGF, MDC, FGF-4 and IGFBP-2,
but also involves ERK, PI3K-AKT-mTOR and PKC signaling pathways as
modulators of this process. Besides, our studies also indicate that CaSR
attenuates constitutive secretion of IL-6 and β-NGF and, via crosstalk
with EGF and IL-6 signaling pathways. In contrast, in normal breast
cells, CaSR promotes secretion of IL-6, GRO and IL-8 and reduces the
constitutive secretion of RANTES, Angiogenin and Oncostatin M. Thus,
our data indicate that CaSR-dependent mechanisms of secretion are al-
tered upon cell transformation.2. Materials and methods
2.1. Antibodies, DNAs and chemicals
VEGF (recombinant human vascular endothelial growth factor,
VEGF165) was purchased from PeproTech; EGF (recombinant human
epidermal growth factor) from Invitrogen; LPA (L-a-lysophosphatidic
acid, oleoyl, sodium), BIM (Bisindolylmaleimide I), Rapamycin and
Anti-protein kinase Bα (PKBα/AKT1) were purchased from Sigma-
Aldrich. HGF (recombinant human hepatocyte growth factor) was
from R&D Systems. PTX (Pertussis Toxin), AG-1478 andWortmannin
(Wn) were purchased from Calbiochem. UO126 (MEK1/2 Inhibitor),
anti-phospho-p44/42 mitogen-activated protein kinase (MAPK, Thr-
202/Tyr-204), anti-S6 Ribosomal Protein (S6) and anti-pS6 (Ser240/
244) were purchased from Cell Signaling. Anti-rabbit IgG (H + L)
and anti-mouse IgG (gamma), human serum adsorbed and peroxi-
dase labeled, were purchased from KPL, NPS-2143 and R-568
compounds were purchased from Tocris Bioscience. Anti-CaSR
monoclonal antibodies 7F8, 1A8, LRG and ADD were kindly donated
by Allen Spiegel (NIDDC-NIH). CaSR Δ895-1075 deletion mutant
was obtained by mutagenesis using the QuickChange™ kit
(Stratagene) and characterized as previously described [41].
shRNA-CaSR was kindly donated by Laurie K. McCauley (University
of Michigan).2.2. Cell lines and transfections
Human breast adenocarcinoma MDA-MB-231, Porcine Aortic Endo-
thelial (PAE) cells, Human embryonic kidney-293T (HEK-293T) and
HeLa cells were routinely grown in DMEM (Dulbecco's Modiﬁed Eagle
Medium, Sigma) supplemented with 5% or 10% of FBS (Fetal Bovine
Serum, GIBCO). MCF-12A normal mammary epithelial cells were
grown in DMEM and Ham's F12 medium mixed 1:1, supplemented
with 10% of FBS, 0.12 UI/ml insulin, 10 ng/ml human epidermal growth
factor, 9 ng/ml cholera toxin and 0.4 μg/ml hydrocortisone. MDA-MB-
231 cells were transfectedwith 5 μ/plate of DNAby using Lipofectamine
LTX and PLUS reagents (Invitrogen), according to themanufacturer's in-
structions. Brieﬂy, 2 μl of PLUS reagent was mixed with either 5 μg of
shRNA empty vectors, shRNA-CaSR or CaSRΔ895-1075 deletionmutant
in 500 μl serum-free DMEM and incubated for 15 min at room temper-
ature. Then, 7 μl of Lipofectamine LTX reagent was added, mixed gently
and incubated for another 30 min. Cells at 60–70% of conﬂuence, in
DMEM medium supplemented with 5% of FBS, were transfected with
the PLUS-DNA-Lipofectamine LTX mixture and incubated for 48 h at
37 °C in 5% CO2. The assays were performed 48 h after transfection.
2.3. Conditioned media
Conﬂuent MDA-MB-231 andMCF-12A cells were serum starvedwith
calcium-free DMEM (Invitrogen) supplemented with 0.25 mM calcium
chloride (low calciummedium) for 24 and 16h, respectively. Then, to ob-
tain conditioned media, the cells were stimulated with different concen-
trations of Ca2+, in the presence or absence of 1 μM R-568, in 1.6 ml of
MIX medium. This medium consisted of 3 volumes of calcium-free
DMEM plus 1 volume DMEM containing 1.8 mM of calcium, but lacking
sodium bicarbonate (MIX medium contains 0.45 mM calcium chloride).
Conditioned media collected at different times post-stimulation were
centrifuged at 13,200 rpm for 10 min at 4 °C, to remove cellular debris,
then dialyzed for 16 h at 4 °C in Tris–EDTA, pH 7.5 (20 mM Tris–HCl,
150mMNaCl, 1mMEDTA) by using SnakeSkin Dialysis tube, 3.5 Kmem-
brane molecular-weight cutoff (Thermo Scientiﬁc). The conditioned
media were lyophilized for 18 h and reconstituted with 370 μl of water
for the experimental assays.
2.4. Western blotting and immunoprecipitation of CaSR
HEK 293-T or HeLa cells were starved of serum for 16 h and stimulat-
ed with conditioned medium obtained from MDA-MB-231 cells (185 μl
of conditioned medium diluted with 315 μl of low calcium medium)
for 10 min. Control cells were stimulated either 10 ng/ml EGF or 10 μM
LPA. After stimulation, cells were washed with ice-cold PBS and lysed
with lysis buffer B (20 mM Tris–HCl pH 7.5, 0.15 M NaCl, 1 mM EDTA,
1% Triton X-100), containing protease and phosphatase inhibitors
(1 mM phenylmethylsulfonyl ﬂuoride, 10 mg/ml aprotinin, 10 mg/ml
leupeptin, 1 mM Sodium Fluoride, 1 mM Sodium Orthovanadate and
10 mM β-glycerol phosphate). Total cell lysates were quantiﬁed by
BCA Method (Pierce Protein Assay 5000-0114), resolved on 10% SDS-
PAGE and transferred to Immobilonmembranes (Millipore Corporation).
Phosphorylation of AKT, ERK1/2 and S6 protein was detected by using
the appropriated antibodies and revealed with Immobilon Western
chemiluminescent substrate (Millipore Corporation). To detect CaSR
expression, proteins in Laemmli sample buffer were not boiled before
electrophoresis. Brieﬂy, cell lysates obtained in lysis buffer B were ho-
mogenized by passing them 5–8 times through a 22-gauge needle and
centrifuged for 15 min at 14,000 rpm at 4 °C. Then, ~30 μg of protein in
Laemmli sample buffer containing β-mercaptoethanol was incubated
at room temperature for 15 min before loading on 7.5% SDS-PAGE. In
this case, nitrocellulose membranes were used for western blots. In a
set of experiments, CaSR was immunoprecipitated from cell lysates of
HEK 293 and HEK 293-T transfected with full-length parathyroid CaSR
by using 2.5 μg of anti-CaSR 7F8 monoclonal antibody (made against
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agarose (Santa Cruz Biotechnology, Inc.) was added and further in-
cubated for an additional 60 min at 4 °C. The protein A/G agaroseFig. 1. CaSR endogenously expressed inMDA-MB-231 breast cancer cells promotes secretion of
cells. (A) Left panel, representativeWestern blot showing endogenous CaSR expression in cell ly
full length CaSR (HEK 293 CaSRWt). (A) Middle panel, representativeWestern blot showing C
pressing or not full-length parathyroid CaSR and developed with LRG antibody (n = 3). (A) Ri
was detected by immunoblot in cell lysates from MDA-MB-231 cells transiently transfected wi
AKT immunoblots served as a loading controls. HeLa (B) orHEK-293T cells (C)were incubated fo
extracellular calcium (0–2.85 mM, as indicated) in the presence or absence of 1 μΜ of R-568 (
phorylation S6, its downstream target) was analyzed by Western blot of total cell lysates. Con
10 ng/ml HGF or 10 μM LPA, as indicated. Representative blots are presented. Graphs represen
experiments, respectively. Error bars indicate S.E.M., *, p b 0.05; **, p b 0.01; ***, p b 0.001
conditioned media (MDA-CM), collected at the indicated times, on the activation of A
above. Representative blots of three independent experiments are presented. Graphs repr
iments. Error bars indicate S.E.M., *, p b 0.05; **, p b 0.01; ***, p b 0.001.was washed four times with buffer B, and the immunoreactive
proteins were eluted in 30 μl of 1X sample buffer containing β-
mercaptoethanol at room temperatures for 15 min before loadingsignalingmolecules that activate AKT, ERK andmTORC1 pathways in HeLa and HEK-293T
sates obtained from the indicated cells and fromHEK-293 cells transiently transfectedwith
aSR immunoprecipitation with 7F8 antibody from HEK-293 and HEK-293T cell lysates ex-
ght panel, representative Western blot showing CaSR knockdown. The expression of CaSR
th CaSR shRNA by using the anti-CaSR monoclonal antibody LRG [48], anti-actin and anti-
r 10minwith dialyzed conditionedmedia fromMDA-MB-231 cells stimulated for 6 hwith
an allosteric modulator of CaSR). Activation of AKT, ERK, and mTORC1 (assessed by phos-
trols included cells in 0.25 mM calcium (shown in the ﬁrst lane) or cells stimulated with
t the relative phosphorylation of AKT, ERK and S6 in four (B) and three (C) independent
. (D) Time-course of stimulation of CaSR in MDA MB-231 cells and effect of dialyzed
KT, ERK and mTORC1 signaling pathways in HEK-293T cells, assessed as indicated
esent the relative phosphorylation of AKT, ERK and S6 from three independent exper-
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LRG anti-CaSR antibodies (made against synthetic peptides corre-
sponding to amino acids 214–235 and 374–391 of the CaSR protein,
respectively). Densitometric quantitation of Western blots was
done with the ImageJ software (http://rsbweb.nih.gov/ij/).Fig. 2. Proﬁle of cytokines and growth factors secreted by MDA-MB-231 breast cancer cells in
ulated for 6 hwith 1.85mMcalcium+1 μMR-568 or left in low calciummedia (0.25mMcalciu
speciﬁc CaSR shRNA. Conditionedmedia were collected, dialyzed, lyophilized and analyzedwith
as described in Section 2, respectively. (A) Representative arrays showing the cytokines detect
media (0.25 mM calcium), or stimulated with extracellular calcium (1.85 mM) and R-568 (
(addedone hour before andduring calciumandR-568 stimulation) (middle panels) orwith the
in 3 independent experiments. Error bars indicate S.E.M., *, p b 0.05; ***, p b 0.001. (C) Bar rep
(D) Representative array showing the growth factors detected in the conditionedmedia fromM
cium and R-568 or incubated in conditions in which CaSR was antagonized with NPS-2143. (E
relative amount of β-NGF detected.2.5. Migration assay
Migration assays were performed in a 12 well Boyden chamber as
described previously [42]. Brieﬂy, conﬂuent PAE cells grown in 100-
mm Petri dishes were serum-starved in low calcium medium for 15 h.response to CaSR stimulation. Serum starved MDA-MB-231 breast cancer cells were stim-
m) either in the absence or presence of a CaSR antagonist (NPS-2143) or transfectedwith a
the Human Cytokine Kit RayBio® Array 3 and Human Growth Factor Kit RayBio® Array 1
ed in the conditioned media from MDA-MB-231 breast cancer cells either in low calcium
left panels), or incubated in conditions in which CaSR was antagonized with NPS-2143
shRNA-CaSR (right panels). (B)Graphs represent the relative amount of cytokines detected
resents the relative amount of IL-6 detected in 3 independent experiments, ***, p b 0.001.
DA-MB-231 breast cancer cells left in 0.25 mM calcium, stimulated with extracellular cal-
) Graphs represent the relative amount of the growth factors detected. (F) Represents the
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suspended in low calcium medium and placed in the upper wells
(100,000 cells/well) of the Boyden chamber. The bottom wells of the
chamber were previously ﬁlled with 159 μl of conditioned medium
from MDA-MB-231 or MCF-12A cells, or 10 ng/ml of HGF (Hepatocyte
growth factor) for positive controls, and covered with polycarbonate ﬁl-
ters having 8-μmpores (Neuro Probe, Inc.). Filterswere previously coated
with 2% bovine skin gelatin (Sigma-Aldrich) for 2 h at 37 °C. Chambers
were incubated in a 5% CO2 atmosphere at 37 °C for 6 h. Then ﬁlters
were ﬁxed with methanol, stained with 10 mg/ml crystal violet (Sigma-
Aldrich) and non-migrating cells were removed from the upper side of
the ﬁlter with a cotton swab. Densitometric analysis of cell migration
was determined with ImageJ software (http://rsb.info.nih.gov/ij/).
2.6. In vitro angiogenesis assay
PAE cells cultured in 100-mmdisheswere serum-starved in low cal-
ciummedium for 15 h. In vitro angiogenesis assays were done in 8 wellFig. 3. CaSR promotes secretion of endothelial chemotactic factors byMDA-MB-231metastatic
extracellular calcium (0–2.85mM, as indicated) in the presence or absence of 1 μMR-568 (an al
(MDA-CM)were collected, dialyzed and its effect on chemotaxis was tested in Boyden chambe
migration, deﬁnedwith respect to the effect ofHGF, resulted fromdensitometric analysis of scan
with 10 ng/ml HGF were considered as negative or positive controls, respectively. A representa
experiments. Error bars indicate S.E.M., **, p b 0.01; ***,p b 0.001differencewith respect to the e
CaSR in MDA-MB-231 cells and effect of conditioned media (MDA-CM), collected at the indica
shown. Graphs represent the densitometric analysis of migrating cells in four independent exp
dicate S.E.M., **, p b 0.01; ***, p b 0.001 difference with respect to the effect in the parallel groustripes of 96-well plates loaded with 35 μl of ice-cold Matrigel (BD Bio-
sciences Matrigel basement membrane matrix, 354230) previously di-
luted 1:2 in serum-free DMEM supplemented with antibiotics. Before
loading the cells, plates were initially incubated at 37 °C for 45 min;
then supplemented with 25 μl of conditioned medium from MDA-MB-
231 cells or from combined cultures of MDA-MB-231 and PAE cells,
co-cultured at different cell ratios, or 10 ng/ml of VEGF as positive con-
trol. The experimentwas initiated by adding10,000 PAE cells (in 25 μl of
low calciummedium) per well, then incubated in a 5% CO2 atmosphere
at 37 °C for 3 h. At the end of the experiments, photographs were taken
from different ﬁelds and the length of tubular networks was deter-
mined using ImageJ software.
2.7. Cytokine and chemokine arrays
The identity of cytokines and growth factors present in the condi-
tioned media from MDA-MB-231 and MCF-12A cells was assessed
using antibody arrays for 42 human cytokines (Cytokine Kit RayBio®breast cancer cells. (A) Conditionedmedia fromMDA-MB-231 cells stimulated for 6 hwith
lostericmodulator of CaSR) was tested as endothelial chemoattractant. Conditionedmedia
rs using serum-starved endothelial PAE cells. Migrating cells were stained and relative cell
nedﬁlters. PAE cells exposed to low calciummedia (0.25mMcalcium) and cells stimulated
tive ﬁlter is shown. Graphs represent the average results of three independent normalized
ffect in theparallel situation inwhich R-568was omitted. (B) Time-course of stimulation of
ted times, on the chemotactic response of PAE endothelial cells. A representative ﬁlter is
eriments and adjusted to the effect of HGF, which was considered as 100%. Error bars in-
p obtained in the absence of 1 μM R-568.
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Human Growth Factor Array 1; RayBiotech, Inc.), according to the
manufacturer's instructions. Brieﬂy, MDA-MB-231 and MCF-12A cells
were serum starved in low calciummedium for 24 or 16 h, respectively,
then stimulated with 1.85 mM Ca2+ and 1 μM of R-568 calcimimetic in
MIX medium at 37 °C for 6 h. In a set of experiments, the cells were in-
cubatedwith AG1478 (700 nM) for 1 h previous and during stimulation
with calcium and R-568. To inhibit CaSR, the cells were incubated with
5 μM NPS-2143 calcilytic for 1 h previous and during treatment with
1.85 mM calcium. In some experiments, to inhibit and deplete IL-6, an
anti-IL-6 antibody (10 μg/ml, PeproTech 500-P26) was included during
the incubation period to obtain conditioned medium from MDA-MB-
231. Then, antigen–antibody complexes were removed by immunopre-
cipitation using protein A-Agarose (Boehringer Mannheim). Only
conditioned media with conﬁrmed chemotactic effect were used forcytokine and growth factor antibody arrays. Lyophilized conditioned
media were reconstituted with 370 μl of water plus 630 μl of blocking
buffer and incubated with the array membranes previously treated
with blocking buffer for 30 min, followed by incubation at room tem-
perature for 2 h. The membranes were washed and incubated with
1 ml of primary biotin-conjugated antibody, diluted 1:250 in blocking
buffer, for 2 h. Then, themembraneswere incubatedwith 2ml of horse-
radish peroxidase-conjugated streptavidin, diluted 1:1000 in blocking
buffer, at room temperature for 1 h and developed with Immobilon
Western chemiluminescent substrate (Millipore Corporation, Billerica,
MA). To prevent saturation of the signal, different exposure times to
the photographic ﬁlm were assessed. The positive signals of cytokine
and growth factorswere quantiﬁedwith the ImageJ software and inten-
sities from each array were normalized by comparison to negative
controls.
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Statistical signiﬁcance of the differences among the data was deter-
mined by multiple-comparison with one-way ANOVA followed by
Bonferroni usingGraphPad Prism, version 4.0, software (GraphPad Soft-
ware, San Diego, CA). A value of p b 0.05 was considered signiﬁcant.
3. Results
3.1. CaSR modulates secretion of chemokines and growth factors by
MDA-MB-231 breast cancer cells
Extracellular calcium is the primary physiological ligand for CaSR
receptor. Knowing that CaSR exerts a tight control on the secretory
pathways of endocrine parathyroid and thyroid cells to adjust the extra-
cellular availability of PTH and calcitonin [26,43,44], we wanted to ex-
plore the role of this receptor as a regulator of secretory properties of
metastatic breast cancer cells. Firstly, we assessed, by Western blot,
the expression of endogenous CaSR protein in diverse cell lines and test-
ed the effectiveness of a speciﬁc CaSR short hairpin RNA, previously
characterized in PC-3prostate cancer cells [45], to reduce the expression
of CaSR in MDA-MB-231 metastatic breast cancer cells. As shown in
Fig. 1A, left panel, the anti-CaSR antibody LRG detected predominant
protein bands between 75 and 150 kDa in total lysates of HEK 293T,
HeLa, PAE,MCF12-A,MCF10-A andMDA-MB-231 cell lines. This pattern
of expression is consistent with the characteristic endogenous expres-
sion of this receptor as reported in other cell types [46]. To further con-
ﬁrm that the band detected by LRG antibodies corresponds to CaSR,
which has been traditionally detectedwith the 7F8 antibody inmultiple
CaSR studies, we used 7F8 antibody to immunoprecipitate CaSR from
cell lysates of HEK-293 and HEK-293T expressing or not full-length
parathyroid CaSR [33,49], and used LRG antibodies to detect byWestern
blot the immunoprecipitated receptors. This approach conﬁrmed that
LRG and 7F8 CaSR antibodies detected the same proteins, revealed as
bands between 75 and 150 kDa (Fig. 1A middle panel). Furthermore,
the speciﬁcity of the LRG antibody for CaSR was previously character-
ized in rat and bovine parathyroid glands [48]. As expected, shRNA-
CaSR effectively reduced the expression of CaSR in MDA-MB-231 breast
cancer cells, regardless of treatment with extracellular calcium and R-
568, without affecting expression of AKT and actin, used as controls
(Fig. 1A right panel). The expression of CaSR inHEK-293T is probably in-
ﬂuenced by the SV40 T-antigen inserted into these cells, as in the case of
TPH1 cells in which differentiation with PMA (phorbol-12-myristate-
13-acetate) promotes CaSR expression (data not shown and [47]).Fig. 4. CaSR antagonists or expression of a CaSR-activatingmutantmodulate the effect of extrac
breast cancer cells. (A) MDA-MB-231 cells transiently transfected with CaSR shRNA or control
calcium either in the presence or absence of 1 μMR-568 and conditioned media were collected
thelial cells. HGF (10 ng/ml)was used as positive control. A representative ﬁlter is shown. Graph
normalized to the effect of HGF, whichwas considered as 100%. Error bars indicate S.E.M. *, p b
absence of R-568, or with respect to the effect of conditionedmedia prepared fromMDA-MB-2
with CaSR antagonistic properties, prevent the secretion of endothelial chemotacticmolecules b
MB-231 cells were incubatedwith 10 μg/ml of 1A8 (CaSR antagonist) or 7F8 (control)monoclo
or absence of 1 μM R-568. Conditioned media (MDA-CM) was collected and tested in chemo
considered as negative control. Graphs represent the densitometric analysis of migrating cells in
sidered as 100%. Error bars indicate S.E.M., **, p b 0.01, difference with respect to the effect in
(MDA-CM) obtained from MDA-MB231 breast cancer cells stimulated with 1.85 mM calcium
the secretion of endothelial chemotactic molecules by MDA-MB231 breast cancer cells stimu
cells were stimulatedwith 1.85mM calcium+1 μMR-568 in the presence or not of NPS-2143 (
media (MDA-CM) were tested in chemotaxis assays with PAE endothelial cells. PAE cells left in
controls, respectively. A representative ﬁlter is shown. Graphs represent the densitometric analy
whichwas considered as 100%. Error bars indicate S.E.M. *,p b 0.05; **, p b 0.01; ***,p b 0.001. (D
molecules by MDA-MB231 breast cancer cells stimulated with extracellular calcium and R-568
control plasmids. Twenty fourhours post transfection cellswere starved of serumand stimulate
CM)were collected, dialyzed and tested in chemotaxis assays with PAE endothelial cells. PAE ce
positive controls, respectively. A representative ﬁlter is shown. Graphs represent the average re
S.E.M. *, p b 0.05. (E) The expression of CaSRΔ895-1075 deletion mutant was detected in total
bands in the blot correspond to mature receptors modiﬁed with N-linked complex carbohydrat
translational addition of carbohydrates [58,59,61].Next, in order to indirectly assess the ability of CaSR to activate MDA-
MB-231 cells to secrete growth factors and cytokines, conditioned
mediawere collected from thesemetastatic breast cancer cells stimulat-
ed with different concentrations of extracellular calcium either in the
presence or absence of 1 μM R-568, a calcimimetic that by itself does
not activate CaSR but signiﬁcantly potentiates its responses [50,51].
Then, the potential of these conditioned media to activate AKT, ERK
and mTOR/S6K/S6 signaling pathways was tested in HeLa and HEK-
293T cells. Consistent with our hypothesis, CaSR activated MDA-MB-
231 breast cancer cells to secrete signaling mediators, as demonstrated
by the positive effect of the respective conditionedmedia (MDA-CM), to
activate AKT, ERK and mTOR signaling pathways both in HeLa (Fig. 1B
left, middle and right panels, respectively) and HEK-293T cells
(Fig. 1C, left, middle and right panels, respectively). Although MDA-
MB-231 cells showed some constitutive secretion of molecules with ag-
onistic properties, time course assays revealed that CaSR signaling ac-
celerated the accumulation of these stimulating molecules in the
conditioned media. A stronger CaSR-dependent effect was evident
after three hours of stimulation with 1.85 mM calcium plus R568, com-
pared to the effect of conditioned media from cells in which CaSR was
not stimulated. A signiﬁcant increase on the activation of AKT, ERK
and mTOR signaling pathways was revealed in HEK293T cells stimulat-
ed with conditionedmedia collected from cells under the effect of CaSR
signaling (Fig. 1D, left, middle and right panels, respectively).
Next, to determine the identity of the molecules secreted by MDA-
MB-231 breast cancer cells upon CaSR activation, conditioned media
were evaluated using human cytokine and growth factor arrays designed
to detect up to 42 cytokines and 41 growth factors. The relative expres-
sion level of these cytokines in the conditioned media from MDA-MB-
231 cells was then detected by a chemiluminescence-based assay after
incubation of dialyzed conditioned media with microarrays containing
cytokine speciﬁc antibodies, to capture the putative secreted molecules
and quantiﬁed by densitometry (Figs. 2A and B). As shown in Fig. 2A,
left lower panel, CaSR stimulation exerted a differential effect on the se-
cretion of cytokines andgrowth factors inMDA-MB-231 cells. It promoted
secretion of GM-CSF (granulocyte-macrophage colony stimulating fac-
tor), EGF (epidermal growth factor) andMDC (macrophage-derived che-
mokine). Compare left lower (stimulated) vs. left upper (control) panels
and Fig. 2B. The role of CaSR as trigger of cytokines and growth factors se-
cretion in these metastatic breast cancer cells was further conﬁrmed by
the inhibitory effect of the selective CaSR antagonist NPS-2143 (Fig. 2A,
middle panels and Fig. 2B) and by inhibiting CaSR expression (Fig. 1A,
right panel) with the shRNA-CaSR (Fig. 2A, right panels and Fig. 2B).
Our results also showed that the secretion of IL-8 (interleukin 8) wasellular calcium on secretion of endothelial chemotactic factors byMDA-MB-231metastatic
vector were starved of serum for 24 h in low calciummedia and stimulated with 1.85 mM
, dialyzed and tested as endothelial chemoattractant in Boyden chambers using PAE endo-
s represent the densitometric analysis ofmigrating cells in three independent experiments
0.05; **, p b 0.01, differencewith respect to the effect of conditionedmedia obtained in the
31 cells transfected with control vector, as indicated. (B) CaSR 1A8monoclonal antibodies,
yMDA-MB-231 breast cancer cells stimulatedwith extracellular calcium and R-568.MDA-
nal antibodies for 1 h before and during stimulation with 1.85mM calcium in the presence
taxis assays using PAE endothelial cells. PAE cells incubated with 0.25 mM calcium were
four independent experiments normalized to the effect of 10 ng/ml HGF, which was con-
the parallel group in which endothelial cells were stimulated with conditioned medium
plus 1 μM R-568 lacking anti-CaSR antibodies. (C) NPS-2143, a CaSR antagonist, prevents
lated with extracellular calcium and R-568. Serum starved MDA-MB-231 breast cancer
added one hour before calcium and R-568) or left in 0.25mM calcium for 6 h. Conditioned
0.25mM calcium and cells stimulated with 10 ng/ml HGF served as negative and positive
sis ofmigrating cells inﬁve independent experiments and normalized to the effect of HGF,
) Effect of activatingCaSRΔ895-1075mutation on the secretion of endothelial chemotactic
. MDA-MB-231 cells were transiently transfected with CaSRΔ895-1075 deletion mutant or
d 1.85mMcalcium in thepresence or absence of 1 μMR-568 and conditionedmedia (MDA-
lls left in 0.25 mM calcium and cells stimulated with 10 ng/ml HGF served as negative and
sults of three independent experiments normalized to the effect of HGF. Error bars indicate
cell lysates byWestern blot (WB) using anti-CaSRmonoclonal ADD antibodies. The higher
es whereas the lower bands correspond to the immature receptors still in process of post-
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negatively modulated the constitutive secretion of IL-6 (interleukin 6),
compare lower left (stimulated) vs. upper left (control) panels and
Fig. 2C,whichwas tightly regulated by CaSR as indicated by the inhibitory
effect of both 5 μM of NPS-2143 and shRNA-CaSR.
Additionally, results obtained with the growth factor array (Figs. 2D
and E) indicated that CaSR promoted secretion of FGF-4 (ﬁbroblast
growth factor-4) and IGFBP-2 (insulin-like growth factor-bindingFig. 5. CaSR promotes secretion of angiogenic factors byMDA-MB-231metastatic breast cancer
CM) collected at 6 h post-stimulation with calcium at different concentrations in the presenc
matrigel. Negative and positive controls corresponded to cells not exposed toMDA-CMor stimu
using ImageJ program and normalized to the effect of VEGF, whichwas considered as 100%. A rep
of three independent experiments. Error bars indicate S.E.M., **, p b 0.01 for the indicated compa
CM) stimulatedwith calcium in the presence or absence of 1 μMR-568, collected at the indicate
ative and positive controls corresponded to cells in 0.25 mM calcium not exposed to MDA-CM
normalized to the effect of VEGF, which was considered as 100%. A representative area of capill
periments. Error bars indicate S.E.M., *, p b 0.05; **, p b 0.01, for the indicated comparisons.protein-2). Likewise IL-6, β-NGF (β-nerve growth factor) was constitu-
tively secreted byMDA-MB-231 cells and secretion of this growth factor
was negatively modulated by CaSR, as indicated by the inhibitory effect
of NPS-2143 treatment (Figs. 2D and F). Coincident with the results ob-
tained with the cytokine array, the results with the growth factor array
conﬁrmed the effect of CaSR on the secretion of EGF and GM-CSF. Alto-
gether, these data demonstrate that CaSR regulates secretion of cyto-
kines and growth factors inmetastaticMDA-MB-231 breast cancer cells.cells. (A) Angiogenic effect of dialyzed conditionedmedia fromMDA-MB-231 cells (MDA-
e or absence 1 μM R-568. Conditioned media were tested using PAE endothelial cells on
latedwith 10 ng/ml of VEGF, respectively. Length of capillary-like structureswas quantiﬁed
resentative area of capillary-like structures is shown. Graphs represent the average results
rison. (B) Angiogenic effect of dialyzed conditionedmedia fromMDA-MB-231 cells (MDA-
d times post-stimulation, were tested in vitro using PAE endothelial cells onMatrigel. Neg-
or stimulated with 10 ng/ml of VEGF, respectively. Length of capillary-like structures was
ary-like structures is shown. Graphs represent the average results in four independent ex-
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MDA-MB-231 metastatic breast cancer cells
We hypothesized that CaSR has an angiogenic role by inducing
MDA-MB-231 metastatic cells to secrete signalingmediators able to ac-
tivate endothelial cell migration and in vitro angiogenesis. In order to
start addressing this possibility, we ﬁrst evaluated a potential direct ef-
fect of extracellular calcium on PAE cell migration by directly treating
these endothelial cells with 0.85 to 2.85 mM of extracellular calcium
in the presence of R-568. As shown in Supplemental Fig. 1A, activation
of CaSR induced just a marginal effect on endothelial cell migration.Next, we tested the ability of dialyzed conditioned media from CaSR-
stimulated MDA-MB-231 cells to support endothelial cell migration
(themediawere dialyzed to avoid any potential direct effect of extracel-
lular calcium on endothelial cells). As shown in Fig. 3A, conditioned
media collected from MDA-MB-231 cells treated with increasing con-
centrations of extracellular calcium in the presence of R-568 induced a
signiﬁcant chemotactic effect on PAE cells. This effect showed a magni-
tude comparable to the chemotactic action of HGF (10 ng/ml) used as
positive control. The secretion of endothelial chemotactic factors by
MDA-MB-231 cells depended on the time of stimulation of CaSR,
reaching a peak at six hours, as demonstrated by a signiﬁcant
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and 12 h (Fig. 3B). However, at 24 h post-stimulation, the chemotactic
activity of conditionedmediawas reduced, probably indicating desensi-
tization of CaSR and turnover of chemotactic factors.
3.3. CaSR knockdown, antagonists or expression of a CaSR activating
mutant modulate the stimulatory effect of extracellular calcium on
endothelial chemotactic factors secretion by MDA-MB-231 metastatic
breast cancer
To further deﬁne the role of CaSR on the secretory properties of
MDA-MB-231 breast cancer cells, we used various independent com-
plementary approaches. Initially, to fully conﬁrm the involvement of
CaSR as trigger of endothelial chemotactic factors secretion by MDA-
MB-231metastatic breast cancer cells, we tested the potential inhibito-
ry effect of the shRNA-CaSR that efﬁciently reduced CaSR expression
(Fig. 1A, right panel). As shown in Fig. 4A, conditioned media obtained
from MDA-MB-231 cells transfected with shRNA-CaSR displayed less
chemotactic effect on PAE cells. Once conﬁrmed that CaSR endogenous-
ly expressed in MDA-MB-231 cells was indeed the receptor of extracel-
lular calcium that promoted secretion of endothelial chemotactic factors
by these breast cancer cells, we aimed to address the effect of CaSR an-
tagonists on this process. Then, monoclonal antibodies against CaSR
were included during the incubation of MDA-MB-231 cells with extra-
cellular calcium and R-568. As shown in Fig. 4B, conditioned medium
fromMDA-MB-231 cells treatedwith 10 μg/ml of 1A8, amonoclonal an-
tibody with antagonistic properties [52], for one hour before the treat-
ment with calcium and R-568 and throughout the time of stimulation,
signiﬁcantly decreased the ability ofMDA-MB-231 cells to secrete endo-
thelial chemotactic factors, as revealed by a reduced effect of these
media on PAE cell migration.Whereas 10 μg/ml of 7F8, a control mono-
clonal antibody that recognizes CaSR but does not signiﬁcantly alter its
function, did not interfere with the secretion of chemotactic factors by
MDA-MB-231 cells. In addition, we investigated the effect of NPS-
2143, a calcilytic known as a selective antagonist of CaSR [53–57]. As
shown in Fig. 4C, conditioned medium fromMDA-MB-231 cells treated
with 5 μMNPS-2143 lacked signiﬁcant chemotactic activity on PAE cells.
The chemotactic effect was also reduced when NPS-2143 was present
during calcium and R-568 stimulation. Furthermore, we tested a gain
of function approach by assessing the effect of the CaSRΔ895-1075mu-
tant, a CaSR deleted at the carboxyl-terminus, known as an activating
mutant associated to autosomal dominant hypocalcemia [58], on the
ability of MDA-MB-231 cells to secrete endothelial chemotactic factors
in response to extracellular calcium. This activating CaSR mutant
transfected into MDA-MB-231 cells signiﬁcantly increased their abilityFig. 6. Secretion of angiogenic factors byMDA-MB-231metastatic breast cancer cells in response
a CaSR activating mutant. (A) CaSR knockdown inhibits the angiogenic effect of MDA-MB-231 c
shRNA or control vector (pENTR) were stimulatedwith 1.85 mM calcium either in the presence
in vitro angiogenesis assays were performed with PAE endothelial cells on Matrigel. Negative a
stimulatedwith 10 ng/ml of VEGF, respectively. Length of capillary-like structureswas normaliz
structures is shown. Graphs represent the average results of three independent experiments. Er
monoclonal antibodies inhibit the angiogenic effect of MDA-MB-231 cells exposed to extracellu
tagonistic properties) or 7F8 (anti-CaSR control)monoclonal antibodies before andduring stimu
(MDA-CM)were used to perform in vitro angiogenesis assayswith PAE endothelial cells. Negati
or stimulated with 10 ng/ml of VEGF, respectively. Length of cord-like structures was normaliz
structures is shown. Graphs represent the average results of four independent experiments. Er
2143 (a CaSR antagonist) inhibits the angiogenic effect of MDA-MB-231 cells exposed to extra
1.85 mM calcium either in the presence or absence of 1 μM R-568 or 5 μM of CaSR calcilytic N
controls corresponded to cells in 0.25 mM calcium not exposed to MDA-CM or exposed to MDA
medium; as positive control, cells were stimulated with 10 ng/ml of VEGF. Length of capillary-l
sentative area of tube-like structures is shown. Graphs represent the average results of ﬁve inde
comparisons. (D) CaSRΔ895-1075 activating deletion mutant enhances the angiogenic effect of
MDA-MB-231 cells expressing the CaSRΔ895-1075 activating deletion mutant stimulated with
angiogenesis assays with PAE endothelial cells. Negative and positive controls corresponded to
capillary structures was normalized to the effect with VEGF, which was considered as 100%. A r
three independent experiments. Error bars indicate S.E.M., *, p b 0.05 for the indicated comparto secrete chemotactic factors that induced endothelial cell migration
(Fig. 4D). The expression of CaSR Δ895-1075 mutant was conﬁrmed in
total cell lysates of transfected MDA-MB-231 cells (Fig. 4E) by using
the ADD antibody, which recognizes an epitope at the extracellular do-
main of full-length parathyroid CaSR. This antibody is known to detect
two major bands of approximately ~150 and 130 kDa. Previous studies
have shown that the ~150 kDa band represents mature receptors mod-
iﬁedwithN-linked complex carbohydrates,whereas the ~130 kDaband
represents immature receptors still in the process of posttranslational
addition of carbohydrates [59–61]. This ADD antibody was useful to dif-
ferentiate the CaSR Δ895-1075 mutant from the CaSR endogenously
expressed in cells used in this study (Fig. 4E and Supplemental Fig. 1B,
left panel); therefore, we used this tool to demonstrate the expression
of transfected CaSR Δ895-1075 mutant. Altogether, these results prove
that CaSR promotes secretion of endothelial chemotactic factors by
MDA-MB-231 cells.3.4. CaSR promotes secretion of angiogenic factors by MDA-MB-231
metastatic breast cancer cells
The secretion of endothelial chemotactic factors by MDA-MB-231
breast cancer cells stimulatedwith extracellular calcium and R-568 sug-
gest that CaSR might have an angiogenic effect dependent on this pro-
cess. In order to assess this possibility, we tested the effect of MDA-
MB-231 conditioned media on in vitro angiogenesis assays carried out
with PAE endothelial cells. As shown in Fig. 5A, left panel, conditioned
media from MDA-MB-231 breast cancer cells, in which CaSR was stim-
ulated, induced an angiogenic response, which was statistically signiﬁ-
cant when endothelial cells were stimulated with conditioned media
collected frombreast cancer cells stimulatedwith 1.85mMextracellular
calcium in the presence of 1 μM R-568 (Fig. 5A, right panel). As expect-
ed, VEGF, one of the best characterized angiogenic factors, used here as
positive control, promoted a positive angiogenic response (Figs. 5A and
B).
Additionally, we characterized the effect of time course stimulation
of CaSR endogenously expressed in MDA-MB-231 cells on their ability
to secrete angiogenic factors. As shown in Fig. 5B, up to 24 h of stimula-
tion of MDA-MB-231 cells with 1.85 mM calcium and 1 μM R-568 in-
duced an angiogenic response revealed by the formation of more
interconnected capillary-reminiscent structures similar to those gener-
ated in response to 10 ng/ml VEGF, used as a positive control. Thus, ad-
ditional in vitro angiogenesis experiments were done with conditioned
medium obtained from MDA-MB-231 cells stimulated with 1.85 mM
extracellular calcium and 1 μM R-568 for 6 h.to extracellular calcium is affected by CaSR knockdown, CaSR antagonists or expression of
ells exposed to extracellular calcium.MDA-MB-231 cells transiently transfectedwith CaSR
or absence of 1 μMof R-568. Conditioned media (MDA-CM) were collected; dialyzed and
nd positive controls corresponded to cells in 0.25 mM calcium not exposed to MDA-CM or
ed to the effect of VEGF,whichwas considered 100%. A representative area of capillary-like
ror bars indicate S.E.M. *, p b 0.05 for the indicated comparisons. (B) Antagonist anti-CaSR
lar calcium. MDA-MB-231 cells were incubated with 10 μg/ml of 1A8 (anti-CaSR with an-
lationwith 1.85 mMcalcium in thepresence or absence of 1 μMR-568. Conditionedmedia
ve and positive controls corresponded to cells in 0.25 mMcalciumnot exposed toMDA-CM
ed to the effect of VEGF, which was considered as 100%. A representative area of tube-like
ror bars indicate S.E.M. **, p b 0.01; ***, p b 0.001 for the indicated comparisons. (C) NPS-
cellular calcium. Conditioned media (MDA-CM) from MDA-MB-231 cells stimulated with
PS-2143 were tested on in vitro angiogenesis assays with PAE endothelial cells. Negative
-CM obtained fromMDA-MB-231 cells incubated with R-568 or NPS-2143 in low calcium
ike structures was normalized to the effect of VEGF, which was considered 100%. A repre-
pendent experiments. Error bars indicate S.E.M., **, p b 0.01, ***, p b 0.001 for the indicated
MDA-MB-231 cells exposed to extracellular calcium. Conditioned media (MDA-CM) from
1.85mM calcium either in the presence or absence of 1 μM R-568 were tested on in vitro
cells not exposed toMDA-CMor stimulatedwith 10 ng/ml of VEGF, respectively. Length of
epresentative area of capillary structures is shown. Graphs represent the average results of
isons.
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cells in response to extracellular calcium is affected by CaSR knockdown, CaSR
antagonists or expression of a CaSR activating mutant
To further characterize the participation of CaSR on the angiogenic
properties of MDA-MB-231 breast cancer cells, we used the same setFig. 7. CaSR induces a paracrine network between breast cancer cells and endothelial PAE cells. A
24 h in low calciummedium and stimulatedwith 1.85mMcalcium either in the presence or abs
B) chemoattractant in Boyden chambers using serum-starved endothelial PAE cells. HGF (10 n
densitometric analysis of migrating cells in three independent experiments normalized to th
1.85 mM calcium in the presence of R-568, which was considered as 100%. Error bars indicate
cells grown at the indicated ratios and stimulated with 1.85 mM calcium in the presence or ab
endothelial cells on matrigel. Negative and positive controls corresponded to cells in 0.25 mM c
tively. Length of capillary-like structureswas quantiﬁed using ImageJ program andnormalized t
1.85 mM calcium in the presence of R-568, which was considered as 100%. A representative are
pendent experiments. Error bars indicate S.E.M., **, p b 0.01 for the indicated comparison.of approaches applied to study the chemotactic properties of condi-
tioned media secreted by these cells. First, we assessed the angiogenic
effect of conditioned media from CaSR-knockdown MDA-MB-231 met-
astatic breast cancer cells. As shown in Fig. 6A, knockdown of CaSR in
MDA-MB-231 cells resulted in a lower response of these cells to secrete
angiogenic factors upon incubation with extracellular calcium, as)MDA-MB-231 and PAE cells co-cultured at the indicated ratios were starved of serum for
ence of 1 μMR-568 and conditionedmediawere collected, dialyzed and tested its effect as
g/ml) was used as positive control. A representative ﬁlter is shown. Graphs represent the
e effect of conditioned media obtained from 1 × 106 MDA-MB-231 cells stimulated with
S.E.M. *, p b 0.05. C) Angiogenic effect of conditioned media from MDA-MB-231 and PAE
sence 1 μM R-568 or left in 0.25 mM calcium. Conditioned media were tested using PAE
alcium not exposed to conditioned medium or stimulated with 10 ng/ml of VEGF, respec-
o the effect of conditionedmedia obtained from1×106MDA-MB-231 cells stimulatedwith
a of capillary-like structures is shown. Graphs represent the average results of three inde-
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on PAE endothelial cells. Next, we explored the effect of CaSR antago-
nists on the secretion of angiogenic factors by MDA-MB-231 cells.
Hence, we included monoclonal antibodies against CaSR during the
stimulation of MDA-MB-231 cells with extracellular calcium and R-
568. As shown in Fig. 6B, incubation of breast cancer cells with 1A8,
the monoclonal antibody with antagonistic properties, decreased the
ability of these cells to secrete endothelial angiogenic factors, whereas
the control 7F8 antibody did not have an effect on this process
(Fig. 6B). Furthermore, NPS-2143 antagonized the effect of CaSR on
the angiogenic response elicited by conditioned medium obtained
fromMDA-MB-231 cells stimulatedwith 1.85mMextracellular calcium(Fig. 6C), but had just amarginal effect in the conditions in which R-568
was also included. In contrast, the CaSR-Δ895-1075 activating mutant
exerted a stronger effect on the ability of MDA-MB-231 cells to secrete
angiogenic factors in response to extracellular calcium (Fig. 6D). These
results demonstrate an angiogenic role played by CaSR by promoting
secretion of angiogenic factors by MDA-MB-231 cells.
3.6. CaSR induces a paracrine network from breast cancer cells to
endothelial PAE cells
Considering that CaSR is also endogenously expressed in PAE cells
(Fig. 1A, left panel), wewanted to knowwhether a paracrinemechanism
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potentially elicited by co-stimulation of MDA-MB-231 and PAE cells.
Thus, we co-cultured these breast cancer and endothelial cells at equal
numbers (one million cells each) or at 1:2 or 2:1 cell ratios (Fig. 7A);
cells were starved with low calciummedium and stimulated with either
1.85mM calcium+1 μMR-568 or left in low calciummedium. The con-
ditioned media collected were analyzed on migration and angiogenesis
experiments using PAE cells. As shown in Fig. 7B, the chemotactic effect
of conditionedmedia fromMDA-MB-231 cellswas increasedwhen these
cellswere co-cultured and co-stimulated togetherwith PAE cells at equal
amount of cells, but this effect was reduced when the amount of PAE
cells was higher than that of MDA-MB-231 cells, whereas PAE cells by
themselves had a limited ability to secrete chemotactic factors in re-
sponse to CaSR stimulation. In contrast, the angiogenic effect of MDA-
MB-231 cells was not further increased when these cells were co-
cultured with PAE endothelial cells, which by themselves showed a
more limited ability to secrete angiogenic factors in response to CaSR
stimulation (Fig. 7 C).
3.7. CaSR signaling pathways involved in the secretion of cytokines and
endothelial chemotactic factors by MDA-MB-231 metastatic breast cancer
cells
CaSR exerts most of its cellular effects through the predominant ac-
tivation of Gαq/11 and Gαi signaling pathways [2,8]. However, G
protein-independent signaling pathways, transactivation of growth fac-
tor receptors, as well as unusual G protein coupling in transformed cells
have been reported to be activated by this receptor [21,32,33,36,62,63].
Therefore, we studied the role of different signaling pathways to further
understand their potential involvement in the secretion of chemotactic
and angiogenic factors promoted by CaSR in MDA-MB-231 breast can-
cer cells. As shown in Fig. 8A, consistent with the results shown in
Fig. 2, MDA-MB-231 cells secreted GM-CSF, EGF, MDC, GRO and IL-6;
being the secretion of the ﬁrst three signiﬁcantly higher in cells in
which CaSR was stimulated; whereas constitutive IL-6 secretion was
signiﬁcantly reduced as a consequence of CaSR stimulation. Thus, we
wanted to know whether EGFR transactivation and constitutive secre-
tion of IL-6 played a role on the secretion of other cytokines. To assess
this question, MDA-MB-231 cells were incubated either with AG-
1478, an inhibitor of EGFR kinase or anti-IL-6 neutralizing antibodies,
before and during incubation with extracellular calcium and R-568;
then, the presence of cytokines in the conditioned media was detected
as described before. As shown in Figs. 8A and B, inhibition of EGFR tyro-
sine kinase activity with AG-1478 prevented the effect of CaSR as a trig-
ger of secretion of the cytokines otherwise sensitive to CaSR stimulation
in MDA-MB-231 cells. Unexpectedly, the secretion of IL-8 and GRO was
increasedwhen conditionedmediumwas obtained in low calciumwith
the presence of AG-1478 (Fig. 8A,middle panel and 8B). In addition, AG-
1478 contributed to inhibit the secretion of IL-6 in these breast cancerFig. 8. CaSR signaling pathways involved in the secretion of cytokines and endothelial chemotac
of EGFR and constitutive secretion of IL-6 contribute to the effect of extracellular calcium on the
breast cancer cells left in 0.25M calcium or stimulated for 6 h with 1.85 mM calcium+1 μMR-
before calcium and R-568), were analyzed with the Human Cytokine Kit RayBio® Array 3 as de
ditioned medium of MDA-MB-231 breast cancer cells either left in 0.25 mM calcium or stimula
EGFR tyrosine kinase activity was inhibited with AG-1478 (middle panels) or IL-6 in the condit
representative blot from2 independent experiments indicating the cytokines detected. (B)Grap
bars indicate S.E.M., *, p b 0.05; ***, p b 0.001 for the indicated comparisons. (C) Graph represen
indicated comparisons. (D) CaSR signaling pathways involved on the secretion of chemotactic fa
231 cells were preincubated with PTX (200 ng/ml) for 20 h or with Wortmannin (300nM, Wn
Then cells were stimulated for 6 hwith 1.85 mMcalcium+1 μMR-568. Conditionedmedia (MD
Negative and positive controls corresponded to cells in 0.25 mM calcium not exposed to MDA-
analysis of migrating cells from six independent experiments adjusted to the effect of HGF, whic
respect to the effect of conditionedmedia obtained fromMDA-MB-231 cells stimulatedwith 1.85
secretion of chemotactic factors byMDA-MB-231 cells exposed to extracellular calcium. Antagon
teins 3 and 5), were included during MDA-MB-231 cells stimulation for 6 h with 1.85 mM calc
chemotaxis (E) and angiogenesis (F) assays using PAE endothelial cells. Negative and positive
with 10 ng/ml of HGF, respectively. Graphs represent the densitometric analysis of migrating ce
adjusted to the effect of HGF and VEGF, respectively, which were considered 100%. Error bars icells (Fig. 8A, middle panel and 8C). In the case of anti-IL-6 neutralizing
antibodies, they attenuated the secretion of GM-CSF, EGF and MDC in
response to CaSR stimulation (Fig. 8A, left panel and 8B, black bars).
As expected, anti-IL-6 neutralizing antibodies effectively depleted IL-6
fromMDA-MB-231 conditionedmedia (Fig. 8C, black bar). Interestingly,
we also found that by depleting IL-6, the secretion of IL-8 and GRO was
further increased in conditionedmedium obtained in low calcium com-
parable to the situation in which EGFR tyrosine kinase activity was
inhibited (Fig. 8A, right panel and 8B, dark gray bars); in both cases,
this effect was sensitive to the action of CaSR.
Next, we explored the chemotactic properties, on endothelial cells, of
conditioned media obtained fromMDA-MB-231 cells in which CaSR was
stimulated in the presence of different inhibitors of various components
of their putative signaling pathways.We examined the effect of PTX (per-
tussis toxin), and inhibitor of Gαi; Wortmannin and rapamycin, inhibi-
tors of PI3K (phosphatidylinositide 3-kinase) and mTORC1 (mammalian
target of rapamycin complex 1), respectively; bisindolylmaleimide I
(BIM), an inhibitor of protein kinase C and UO126, a dual inhibitor of
MEK1 & MEK2 (Mitogen-activated protein kinase kinase 1 & 2). As
shown in Fig. 8D, all these inhibitors decreased the chemotactic activity
displayed by conditioned media obtained from MDA-MB-231 cells ex-
posed to extracellular calcium together with R-568. In addition, AG-
1478, the inhibitor of EGFR tyrosine kinase that decreased the secretion
of diverse chemokines as indicated before, also inhibited the presence
of endothelial chemoattractants in the conditioned medium of MDA-
MB-231 breast cancer cells in which CaSR was stimulated.
Additionally, knowing that CaSR stimulates secretion of Wnt5a
(wingless protein 5a) in colonic myoﬁbroblasts and in HT-29 colon can-
cer cells [64,65], that Wnt (wingless) signaling regulates growth and
differentiation of mammary gland, and that this pathway is altered in
breast cancer [66,67], we investigated whether Wnt5a could be in-
volved in the underlying mechanism supporting the secretion of cyto-
kines and angiogenic factors promoted by CaSR in MDA-MB-231
breast cancer cells. Hence, we obtained conditioned media in the pres-
ence or absence of inhibitors of Wnt signaling, either SFRP3 or SFRP5
(secreted frizzled-related proteins 3 and 5), known to attenuate Wnt
signaling by interfering in the binding of Wnt proteins to their frizzled
receptors [68,69]. As shown in Fig. 8E–G, none of these Wnt signaling
antagonists regulated the chemotactic and angiogenic activity displayed
by conditioned media fromMDA-MB-231 cells. These data suggest that
CaSR promotes secretion of angiogenic and chemotactic factors by
MDA-MB-231 cells through diverse signaling pathways, including
PI3K/AKT/mTOR and transactivation of EGF receptors, without the in-
tervention of Wnt signaling.
Finally, we wanted to know the effect of CaSR as a potential promot-
er of secretion of cytokines and growth factors by normal breast cells. To
assess this, we evaluated the effect of extracellular calcium and R-568
on the secretory potential of MCF-12A cells, which we previously dem-
onstrated that endogenously express CaSR (Fig. 1A, left). This cell linetic factors byMDA-MB-231metastatic breast cancer cells. CaSR-dependent transactivation
secretory potential of MDA-MB-231 cells. Conditionedmedia obtained fromMDA-MB-231
568, in the presence or not of AG-1478 or anti-IL6 neutralizing antibodies (added one hour
scribed in Section 2. (A) Representative arrays showing the cytokines detected in the con-
ted with extracellular calcium and R-568 (left panels), or incubated in conditions in which
ioned media was captured with neutralizing antibodies (right panels). The image shows a
hs represent the relative amount of cytokines detected in 2 independent experiments. Error
ts the relative amount of IL-6 detected in 2 independent experiments, ***, p b 0.001 for the
ctors byMDA-MB-231 cells exposed to extracellular calcium. Before stimulation, MDA-MB-
), Rapamaycin (40 ng/ml, Rapa), UO126 (10 μM), BIM (1 μM) or AG1478 (700nM) for 1 h.
A-CM)were collected, dialyzed and tested in chemotaxis assayswith PAE endothelial cells.
CM or stimulated with 10 ng/ml of HGF, respectively. Graph represents the densitometric
h was considered 100%. Error bars indicate S.E.M., *, p b 0.05, **, p b 0.01, ***, p b 0.001with
mMcalcium in thepresence of R-568. (E–F)Wnt signalingpathways is not involvedon the
ists ofWnt signaling, SFRP3 (10 μg/ml) or SFRP5 (50 μg/ml) (secreted Frizzled-related pro-
ium +1 μM R-568. Conditioned media (MDA-CM) were collected, dialyzed and tested in
controls corresponded to cells in 0.25 mM calcium not exposed to MDA-CM or stimulated
lls (E) and the length of capillary-like structures (G) from three independent experiments
ndicate S.E.M., *, p b 0.05, **, p b 0.01 for the indicated comparisons.
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[70,71]. In this case, CaSR activation promoted an increase on the secre-
tion of GRO, IL-6, IL-8, and MCP-1. In addition, some new factors, not
previously detected in MDA-MB-231 cells, were identiﬁed in MCF-12A
cells, these included RANTES (regulated on activation, normal T cell
expressed and secreted), Angiogenin and Oncostatin-M (Fig. 9 A and
B). The secretion of these factors was attenuated upon CaSR stimulation
as well as by NPS-2143 treatment. Our results also indicate that secre-
tion of IL-6 occurs through a mechanism that changes according to
cell context, being promoted by CaSR in normal breast cells but
inhibited in metastatic breast cancer cells. Another evident difference
was detected on the secretion of IL-8 and GRO, which in normal breast
cells was activated by CaSR, while in breast cancer cells was negatively
regulated by IL-6 and EGF signaling networks which, as shown before,
were regulated by CaSR signaling. Altogether, these data demonstrate
that CaSR regulates secretion of cytokines and growth factors in normal
and metastatic breast cancer cells, showing differences between them
that suggest an aberrant regulation of CaSR-dependent secretoryFig. 9. Proﬁle of cytokines and growth factors secreted byMCF-12Anormal epithelial breast cells
CaSR in metastatic cancer and normal breast cells. Serum starved MCF-12A cells were stimu
(0.25 mM calcium). Conditioned media were collected, dialyzed, lyophilized and analyzed
(A) Representative arrays showing the cytokines detected in the conditionedmedia ofMCF-12A
ulatedwith extracellular calcium and R-568 (left panels), or incubated in conditions inwhich Ca
stimulation) (right panels). (B) Representative graph showing the relative amount of cytoki
chemotactic and angiogenic factors by MDA-MB-231 cells (left panel). Brieﬂy, CaSR activation
Gαi-dependent pathways and transactivation of EGFR. Constitutive secretion of IL-6 participa
cytokines, whereas its own secretion is attenuated by CaSR. In normal mammary MCF-12A cell
stitutive secretion of RANTES, Angiogenin and Oncostatin M.mechanisms in the later, while other signaling properties, such as the
activation of ERK, remain comparable (Supplemental Fig. 1C).
4. Discussion
The oncogenic potential of cancer cells increases by the local and
systemic effects of extracellular mediators, including cytokines and
growth factors, secreted in response to hypoxia, overexpression of
growth factor receptors and aberrant signaling of diverse oncogenes,
among other alterations that exacerbate the aggressiveness of trans-
formed cells [72,73]. Via activation of angiogenic processes that pro-
mote growth of new blood vessels as constituents of tumoral stroma,
these extracellular mediators allow tumors to grow beyond the limits
regularly imposed to normal cells, which require being at the proximity
of functional capillaries to have efﬁcient supply of oxygen and nutrients.
In addition, through metastatic events, also stimulated by secreted fac-
tors, transformed cells invade new tissues [74–77]. Our current ﬁndings
demonstrate that CaSR endogenously expressed in metastatic breastin response to CaSR stimulation andmodel depicting differences in the secretory effects of
lated for 6 h with 1.85 mM calcium +1 μM R-568 or incubated in low calcium medium
with the Human Cytokine Kit RayBio® Array 3 as described in Section 2, respectively.
normal breast cells incubated either in low calciummedium (0.25 mM calcium), or stim-
SRwas antagonizedwith NPS-2143 (added one hour before and during calcium andR-568
nes detected. (C) Model depicting CaSR signaling pathways involved in the secretion of
promotes the secretion of GM-CSF, EGF, MDC, IGFBP-2 and FGF-4 via the participation of
tes in positive and negative loops that contribute to the secretion or inhibition of other
s (right panel), CaSR promotes secretion of GRO, IL-6, and IL-8, whereas it attenuates con-
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factors which activate an integrated response in endothelial cells, evi-
denced by increased migratory and angiogenic capabilities, and stimu-
late AKT, ERK and mTOR signaling pathways in different cell types. In
response to CaSR stimulation, MDA-MB-231 breast cancer cells secrete
GM-CSF, EGF, MDC, FGF-4 and IGFBP-2 via a mechanism that requires
transactivation of EGFR and involves ERK, PI3K-AKT-mTOR and PKC sig-
naling pathways. The identiﬁed cytokines and growth factorsmost like-
ly exert an integrated effect on endothelial cells, as independent reports
focusing on individual cytokines and growth factors have demonstrated
their angiogenic potential [78–86]. Thus, our results suggest that the
joint potential of multiple chemotactic and angiogenic mediators se-
creted in response to CaSR activation putatively contributes to the ag-
gressiveness of breast cancer cells.
Although an angiogenic response to tumoral cells is frequently me-
diated by VEGF, the relevance of other angiogenic mediators, secreted
by cancer cells, is revealed by the limited applicability of anti-VEGF
therapies whose effectiveness is restricted to speciﬁc cancers such as
renal cell carcinoma, metastatic colorectal cancer and recurrent glio-
blastoma multiforme [87]. In fact, it has been recently demonstrated
that tumors achieve resistance to anti-VEGF therapy through secreted
factors, in particular IL-17 which promotes secretion of G-CSF and IL-6
[88]. Therefore, identiﬁcation of additional angiogenic factors or, alter-
natively, the characterization of receptors and signaling pathways that
promote secretion of multiple of these factors by cancer cells, opens ad-
ditional possibilities to pursue studies oriented to design improved drug
combinations for therapeutic intervention. Our results imply a previ-
ously not addressed angiogenic potential of CaSR by activating the se-
cretory properties of metastatic breast cancer cells. In this case, we
could not detect VEGF in the conditioned media from MDA-MB-231
cells either by microarrays or byWestern blot (data not shown). In ad-
dition, pro-inﬂammatory cytokines like TNF-α, IL-1α and β, IL/10 or
IFN-γ or additional pro-angiogenic molecules other than VEGF as SDF-
1/CXCL12 could not be detected in the microarrays we used [47,
89–94]. Implying that these cytokines are not involved in the chemotac-
tic and angiogenic effect observed in PAE endothelial cells and
supporting a selective mechanism by which CaSR promotes secretion
of a speciﬁc set of growth factors and cytokines.
In addition, our results show that CaSR attenuates the constitutive
secretion of IL-6 and β-NGF by MDA-MB-231 metastatic breast cancer
cells. Intriguingly, it has been previously reported that CaSR not only
elicits an elevation on the expression and secretion of this proinﬂamma-
tory cytokine, but also its expression is promoted by its signaling effects.
These effects indicate the existence of cell speciﬁc mechanisms by
which CaSR regulates IL-6 secretion [47,95–97]. Accordingly, our results
also reveal that in MCF-12A normal breast cells CaSR stimulation pro-
motes IL-6 secretion implying a change in the secretion mechanism
upon cell transformation. The molecular pathway by which CaSR inter-
feres with constitutive secretion of these cytokines is currently un-
known. Our results indicate some dependence on EGFR signaling,
suggesting a transactivation-mediated event and also an autocrine
loop, as evidenced by the inhibitory effect of anti-IL6 neutralizing anti-
bodies. Our study also demonstrates that IL-8 and GRO secretion is
tightly regulated by EGFR and IL-6 signaling intercommunication
which are further sensitive to CaSR signaling.
The role of CaSR as an inhibitor of the constitutive secretion of vari-
ous cytokines was detected both in cancer and normal breast cells. In
the former, CaSR inhibited secretion of IL-6, while in the later it attenu-
ated secretion of RANTES, Angiogenin and Oncostatin M. These effects
resemble the well-known control that CaSR exerts on PTH [98] and
TNF-α secretion [26].
To our knowledge, this is the ﬁrst report showing a role for CaSR on
the secretion ofmultiple chemotactic and angiogenicmolecules bymet-
astatic breast cancer cells. Knowing the strong therapeutic potential of
inhibiting cancer-derived factors, which might also represent bio-
markers to monitor the effectiveness of antineoplastic treatments, ourresults suggest a therapeutic potential of CaSR as a novel target in breast
cancer.
5. Conclusion
The present study demonstrates that CaSR endogenously expressed
in metastatic MDA-MB-231 breast cancer and normal epithelial cells
promotes secretion of a variety cytokines and growth factors, which in
turn can activate signaling pathways critical to promote endothelial
chemotaxis and a positive in vitro angiogenesis response. The putative
mechanisms, illustrated in Fig. 9, involve a CaSR-dependent control on
the constitutive secretion of β-NGF and IL-6 in an autocrine loop, to-
gether with an inhibitory effect on IL-8 and GRO secretion with the par-
ticipation of transactivated EGFR. CaSR activation promotes release of
Gαi and Gβγ subunits to initiate signaling through PI3K/mTOR path-
ways, PKC and ERK to stimulate secretion of cytokines and growth fac-
tors such as GM-CSF, EGF, MDC, IGFBP-2 and FGF4. Secreted EGF, in
MDA-MB231 cells, regulates the secretion of GM-CSF, MDC, IL-8, IL-6,
and partially GRO (Fig. 9 C, left panel). In the case of normal MCF-12A
cells, CaSR regulates constitutive secretion of RANTES, Angiogenin and
Oncostatin M and CaSR stimulation promotes the secretion of GRO, IL-
6 and IL-8 (Fig. 9 C, right panels). Thus, altogether our ﬁndings suggest
an aberrant regulation of CaSR-dependent secretory mechanisms in
metastatic breast cancer cells thatmight contribute to an indirect angio-
genic potential of this receptor in breast cancer.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.10.011.
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